Novo Nordisk experienced a cybersecurity breach where attackers accessed a limited number of internal IT systems storing personal data. The compromised data included pseudonymized patient information from clinical trials and contact details of healthcare providers. The exposed patient data did not contain direct identifiers such as names or other information that would allow third parties to identify individuals. The company has publicly disclosed the incident but no known exploit or attacker group attribution has been reported.

The breach exposed limited personal data related to clinical trial participants, including pseudonymized identifiers and health-related information, but no direct identifiers were compromised. Healthcare providers' contact information may also have been accessed. The incident does not appear to enable identification of individual patients in the clinical trials. There is no evidence of exploitation or further compromise reported at this time.

No specific remediation or patch information is provided. As this is a disclosed breach incident, Novo Nordisk is responsible for managing the response and mitigation. Organizations should monitor official communications from Novo Nordisk for updates. No immediate action is indicated for external parties based on the available information.